A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Lead Sponsor

Hoffmann-La Roche

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1
•Life expectancy greater than or equal to 3 months
•Histologically or cytologically confirmed metastatic, non-squamous or squamous Non-Small Cell Lung Cancer (NSCLC)
•Measurable disease (at least one target lesion)
•Adequate hematologic and end-organ function
•Tumor accessible for biopsy
•For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating eggs as outlined for each specific treatment arm
•For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm
•No prior systemic therapy for metastatic NSCLC
•High tumor PD-L1 expression, defined as Tumor Proportion Score (TPS) or TCs \>= 50% or TC3
•\- Disease progression during or following treatment for metastatic or locally advanced, inoperable NSCLC

•Prior allogeneic stem cell or solid organ transplantation
•Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
•Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
•History of leptomeningeal disease
•Active or history of autoimmune disease or immune deficiency
•History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
•History of malignancy other than NSCLC within 2 years prior to screening
•Active tuberculosis
•Severe infection within 4 weeks prior to initiation of study treatment

Related studies

NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more

NCT06855771 · Carcinoma, Non-Small-Cell Lung

NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, and more

NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and more

NCT06120140 · Carcinoma, Non-Small-Cell Lung